Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

Company Overview

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing facilities, 9 R&D centres and 9,500 employees worldwide.

Key Stats

• Today's Range: 1,826 to 1,857.16
• 50-Day Range: 1,592 to 1,995
• 52-Week Range: 1,578 to 2,360
• Volume: 654,541 shs
• Average Volume: 1.25 million shs
• Market Capitalization: £4.09 billion
• P/E Ratio: 1,104.79
• Dividend Yield: 0.04%
• Price Target: GBX 2,627.50
• Consensus Rating: Buy

Hikma Pharmaceuticals Stock Analysis - MarketRank™

Hikma Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Hikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Hikma Pharmaceuticals has a consensus price target of GBX 2,627.50, representing about 42.4% upside from its current price of GBX 1,845.

Amount of Analyst Coverage

Hikma Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hikma Pharmaceuticals is 1,104.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 283.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hikma Pharmaceuticals is 1,104.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 77.69.

Price to Earnings Growth Ratio

Hikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hikma Pharmaceuticals has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HIK.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Hikma Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 3.84%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Hikma Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Hikma Pharmaceuticals is 47.90%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.61

Short Interest

There is no current short interest data available for HIK.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.07

News Sentiment

Hikma Pharmaceuticals has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Hikma Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought £3,800,155 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

17.76% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.62% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HIK Stock Analysis - Frequently Asked Questions

How have HIK shares performed this year?

Hikma Pharmaceuticals' stock was trading at GBX 2,002.90 at the beginning of the year. Since then, HIK stock has decreased by 7.9% and is now trading at GBX 1,845.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:HIK
• CIK: N/A
• Web: www.hikma.com
• Phone: +44-20-73992760
• Fax: N/A
• Employees: 9,100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hikma Pharmaceuticals: GBX 2,627.50
• High Price Target: GBX 2,850
• Low Price Target: GBX 2,500
• Potential Upside/Downside: +42.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 1.67
• Trailing P/E Ratio: 1,104.79
• Forward P/E Ratio: 12.10
• P/E Growth: 2.38
• Net Income: £353.21 million
• Net Margins: 9.45%
• Pretax Margin: N/A
• Return on Equity: 12.71%
• Return on Assets: 9.40%

Debt

• Debt-to-Equity Ratio: 55.82
• Current Ratio: 1.66
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: £3.22 billion
• Price / Sales: 1.27
• Cash Flow: GBX 221.25 per share
• Price / Cash Flow: 8.34
• Book Value: GBX 1,027.88 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 221,452,000
• Free Float: N/A
• Market Cap: £4.09 billion
• Optionable: Not Optionable
• Beta: 0.41